Search results
Results from the WOW.Com Content Network
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. [4] [10] It is a small-molecule, orally active, selective neurokinin-3 (NK 3) receptor antagonist which is under development for the treatment of sex hormone-related disorders.
(Reuters) - Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues ...
3 Largest selling pharmaceutical products of 2015. 4 Best selling pharmaceuticals of 2013. 5 See also. ... Astellas Pharma US: Overactive bladder: Feb-2000: 2018-Nov ...
The U.S. government, late last month, selected the first 10 drugs, including the top-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer, which will face price negotiations as part ...
Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. [3]
Zolbetuximab has been tested in two phase III clinical trials for gastric cancer, SPOTLIGHT and GLOW. [11] [12] A combined analysis of the two trials confirmed that zolbetuximab, when added to chemotherapy, improved progression-free survival and overall survival for patients with HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma ...
Results of a Phase I clinical trial were reported in 2016. [6]In December 2019, enfortumab vedotin was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.